Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents

Executive Summary

While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.

You may also be interested in...



Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

Roche's New Chief Medical Officer Levi Garraway Brings Deep Cancer Genomics Expertise

CMO Sandra Horning will retire at the end of the year, to be succeeded by Lilly's former senior VP of oncology R&D on 1 October.

Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies

Lilly is targeting mRNA-based next-generation immunotherapies in its collaboration with Germany's CureVac, which could be worth more than $1.7bn for the family-office backed biotech.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel